Alfredo Sebastián Golemba, Specialist Physician in Oncology at the Caribbean Cancer Center, CECAC Ltd., shared a post on LinkedIn:
“Regardless of the stage, TNBC has a worse prognosis compared to other subtypes of BC. The standard of care for early TNBC (T ≥ 2 cm and/or N+) is neoadjuvant chemoimmunotherapy.
Classically, patients who achieve a pCR have a better prognosis compared to those who do not. Up to 10% of patients with pCR may still relapse.
In 2025, we obtained interesting data regarding the prognosis of TNBC patients who achieve pCR.
In GAMBIT study, TILs and Nodal status are independently prognostic in patients with pCR. Patients with TILs <30% and cN+ have a five times greater risk of death at 5 years.
In GeparNuevo, patients who achieved pCR with immunotherapy, 100% were alive at 7 years compared to 82% of the patients who achieved pCR without immunotherapy. Therefore, in early TNBC, it is not only important to achieve the pCR but also the quality of the pCR.
If pCR after chemoimmunotherapy and sTILs ≥ 30%, is there a role for adjuvant immunotherapy in TNBC.”
More posts on OncoDaily.
